ImmunityBio shared interim results from the company’s ongoing metastatic pancreatic cancer trial, demonstrating overall survival that is double the historical rate.
Cranbury, New Jersey-based Rafael Pharmaceuticals reported disappointing results from two Phase III clinical trials evaluating the safety and efficacy of the cancer metabolism drug CPI-613 (devimistat) when combined with modified FOLFIRINOX (mFFX) as a first-line therapy.
Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.
Britain’s AstraZeneca clinched expanded regulatory backing for two medications, including one for the blockbuster cancer treatment Lynparza, in a development pipeline that now includes a possible coronavirus vaccine.
Rafael Pharmaceuticals Inc. reached an enrollment milestone of more than 250 patients in the company’s pivotal Phase 3 clinical trial for metastatic pancreatic cancer (AVENGER 500), which is evaluating the efficacy and safety of Rafael’s lead compound CPI-613 (devimistat) in combination with modified FOLFIRINOX (mFFX) as first-line therapy.
Halozyme Therapeutics is restructuring after halting development of a metastatic pancreatic cancer drug that failed to demonstrate an improvement in overall survival in a Phase III trial.
Eli Lilly and Co.’s experimental pancreatic cancer treatment in combination with chemotherapy drugs failed to meet the main goal of overall survival in a late-stage study.